TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24121121

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT) using doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) plus involved-field radiation therapy (IFRT)
Number of subjects: 588

Group type: COMPARATOR
Intervention: ABVD alone
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: ABVD in HD10 eligible patients achieving complete response (CR) or unconfirmed complete response (CRu) after two cycles
Number of subjects: 588

Group type: COMPARATOR
Intervention: ABVD in HD.6 eligible patients achieving complete response (CR) or unconfirmed complete response (CRu) after two cycles
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: ABVD in HD10 eligible patients not achieving CR/CRu after two cycles
Number of subjects: 588

Group type: COMPARATOR
Intervention: ABVD in HD.6 eligible patients not achieving CR/CRu after two cycles
Number of subjects: 588
Study: 24121151

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study: 24122237

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment during childhood
Number of subjects: 1204
Study: 24122387

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg daily and dexamethasone 8 mg once weekly (part I)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg daily and dexamethasone 8 mg once weekly plus rituximab 375 mg/m2 (part II)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall treatment (lenalidomide, low-dose dexamethasone, and rituximab)
Number of subjects: 27
Study: 24122452

Group type: EXPERIMENTAL
Intervention: Vasodilator stress CMR
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 151
Study: 24122508

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology
Number of subjects: 46887

Group type: EXPERIMENTAL
Intervention: hrHPV testing
Number of subjects: 46887
Study: 24122716

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 249
Study: 24122913

Group type: EXPERIMENTAL
Intervention: Vertical Auto Profile (Atherotech Inc.)
Number of subjects: 1340614

Group type: EXPERIMENTAL
Intervention: Very Large Database of Lipids 1.0
Number of subjects: 1340614
Study: 24122961

Group type: EXPERIMENTAL
Intervention: DAPT for >3 months
Number of subjects: 56440

Group type: COMPARATOR
Intervention: DAPT for 3 months
Number of subjects: 56440

Group type: EXPERIMENTAL
Intervention: DAPT for >6 months
Number of subjects: 56440
Study: 24123804

Group type: EXPERIMENTAL
Intervention: Platelet counts < 60 × 10(9) /L on postoperative day 5 (POD5)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Platelet counts < 60 × 10(9) /L on POD5
Number of subjects: 257
Study: 24124377

Group type: EXPERIMENTAL
Intervention: Modified relaxation (MR) technique
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control group (health education)
Number of subjects: 432
Study: 24124874

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24125537

Group type: EXPERIMENTAL
Intervention: Heterodigital arterialised nerve pedicle flap
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cross-finger flap and secondary nerve grafting
Number of subjects: 12
Study: 24126237

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) with risedronate
Number of subjects: 63

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) without bisphosphonate therapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Failure to suppress bone turnover markers while receiving ADT
Number of subjects: 63
Study: 24126537

Group type: EXPERIMENTAL
Intervention: Huntington disease
Number of subjects: 334
Study: 24127057

Group type: EXPERIMENTAL
Intervention: Meniscus surgery for traumatic tears
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meniscus surgery for non-traumatic tears
Number of subjects: 0
Study: 24127452

Group type: EXPERIMENTAL
Intervention: Pidilizumab (anti-PD-1 monoclonal antibody), administered as three doses beginning 1 to 3 months after AHSCT.
Number of subjects: 66
Study: 24127479

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 444

Group type: COMPARATOR
Intervention: Control (no palivizumab)
Number of subjects: 444
Study: 24128118

Group type: EXPERIMENTAL
Intervention: REBA MTB-Rifa® assay
Number of subjects: 720

Group type: COMPARATOR
Intervention: Conventional drug-susceptibility testing (DST)
Number of subjects: 720
Study: 24128336

Group type: EXPERIMENTAL
Intervention: Low vitamin A status (serum retinol <1·05 μmol/l)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Low vitamin A status
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Middle vitamin A tertile (1·056-1·298 μmol/l)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Higher concentration of serum retinol
Number of subjects: 391

Group type: COMPARATOR
Intervention: Fe deficiency
Number of subjects: 391
Study: 24128439

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D (1100IU/day) for at least 12 months
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Validation study with 145 extended independent white postmenopausal women
Number of subjects: 446
Study: 24128669

Group type: EXPERIMENTAL
Intervention: BMS-626529 (an attachment inhibitor administered as the prodrug BMS-663068)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS-626529
Number of subjects: 0
Study: 24128715

Group type: EXPERIMENTAL
Intervention: ROS1 rearrangement screening in resected NSCLC patients
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: ROS1 rearrangement screening in advanced pulmonary adenocarcinoma patients
Number of subjects: 515
Study: 24129642

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 111
Study: 24130359

Group type: EXPERIMENTAL
Intervention: Japanese
Number of subjects: 270

Group type: COMPARATOR
Intervention: Caucasians
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Body composition measures (BMI and adipose tissue distribution)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Differences in β-cell response
Number of subjects: 270
Study: 24130489

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for 24 weeks
Number of subjects: 16
Study: 24130673

Group type: EXPERIMENTAL
Intervention: Community-based multimodal intervention for suicide prevention
Number of subjects: 631133

Group type: COMPARATOR
Intervention: Prevention-as-usual control group
Number of subjects: 631133
Study: 24130889

Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 50
Study: 24131282

Group type: EXPERIMENTAL
Intervention: BG-12 240 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BG-12 240 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: BG-12
Number of subjects: 0
Study: 24131779

Group type: EXPERIMENTAL
Intervention: Dinaciclib (0.33 mg/m2 to 14 mg/m2, 2-hour intravenous infusion once weekly for 3 weeks)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dinaciclib at RP2D (12 mg/m2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dinaciclib (various doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dinaciclib (all doses)
Number of subjects: 48
Study: 24132072

Group type: EXPERIMENTAL
Intervention: Condom-Him intervention (experimental arm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control arm (viewing a list of websites containing HIV/AIDS related information)
Number of subjects: 60
Study: 24132357

Group type: EXPERIMENTAL
Intervention: Intraoperative computed tomography (CT) imaging at Center A
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard fluoroscopic imaging at Center B
Number of subjects: 36
Study: 24132613

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg daily
Number of subjects: 0
Study: 24133188

Group type: EXPERIMENTAL
Intervention: PfRH5-specific IgG
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Concentrated PfRH5-specific IgG
Number of subjects: 357
Study: 24134154

Group type: EXPERIMENTAL
Intervention: Teduglutide (subcutaneously for 24 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (subcutaneously for 24 weeks)
Number of subjects: 0
Study: 24134221

Group type: EXPERIMENTAL
Intervention: HIV-1-specific antibody responses to transmembrane glycoprotein (TM) and reverse transcriptase (RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV-1-specific antibody responses to surface glycoprotein (SU), capsid (CA), matrix (MA), and integrase (IN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV-1-specific antibody responses to capsid (CA), matrix (MA), and integrase (IN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV-1-specific antibody responses to capsid (CA) and integrase (IN)
Number of subjects: 0
Study: 24135755

Group type: EXPERIMENTAL
Intervention: Adaptive optics scanning laser ophthalmoscopy (AOSLO) imaging
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard clinical measures
Number of subjects: 7
Study: 24136099

Group type: EXPERIMENTAL
Intervention: Control Preference Scale at baseline (n=405) and 1 year later (n=314)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Shared Decision Making Questionnaire (SDM-Q-9) in a subgroup of patients (n=108)
Number of subjects: 405
Study: 24136113

Group type: COMPARATOR
Intervention: HIV-monoinfected
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: HIV/HCV coinfection
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: HCV in HIV-infected participants
Number of subjects: 569
Study: 24136335

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24136369

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 598
Study: 24136934

Group type: EXPERIMENTAL
Intervention: (18)F-CP-18
Number of subjects: 7
Study: 24138429

Group type: EXPERIMENTAL
Intervention: Fractional polynomial model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Power-law model
Number of subjects: 0
Study: 24138784

Group type: EXPERIMENTAL
Intervention: Strength training during 24 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 94
Study: 24138831

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab
Number of subjects: 15
Study: 24138944

Group type: EXPERIMENTAL
Intervention: Decitabine (DAC) 20mg/m² intravenously daily for 5 days followed by rapamycin at doses of 2 mg, 4 mg, and 6 mg/day from day 6 to day 25
Number of subjects: 12
Study: 24139066

Group type: EXPERIMENTAL
Intervention: ICBT
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IPDT
Number of subjects: 44
Study: 24139613

Group type: EXPERIMENTAL
Intervention: Induction therapy consisting of 2 cycles of cisplatin and etoposide combined with 45 Gy of thoracic radiotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 22
Study: 24140121

Group type: EXPERIMENTAL
Intervention: ApoCell (35, 70, 140, or 210 × 10(6) cell/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ApoCell
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ApoCell (higher doses)
Number of subjects: 13
Study: 24140416

Group type: EXPERIMENTAL
Intervention: Type 1 Brugada pattern on ECG in DM1 patients
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: SCN5A sequencing
Number of subjects: 914

Group type: COMPARATOR
Intervention: Ventricular myocardial specimen analysis
Number of subjects: 914
Study: 24141377

Group type: EXPERIMENTAL
Intervention: Isolated hepatic perfusion (IHP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (longest surviving patients in Sweden with uveal melanoma liver metastases not treated with IHP)
Number of subjects: 34
Study: 24141969

Group type: EXPERIMENTAL
Intervention: Multicomponent technology intervention (internet-delivered programme, portable pedal machine, pedometer for 12 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Wait-list control group (maintained behaviours for 12 weeks)
Number of subjects: 49
Study: 24142996

Group type: EXPERIMENTAL
Intervention: Vorinostat/azacitidine/gemtuzumab ozogamicin
Number of subjects: 52
Study: 24143213

Group type: EXPERIMENTAL
Intervention: Genotype GA/AA of SNP rs2306283 of the gene SLCO1B1
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Genotype GG of SNP rs1051266 of the gene SLC19A1
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Both genotypes (GA/AA of rs2306283 and GG of rs1051266)
Number of subjects: 137
Study: 24144215

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 15 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dipyrone 15 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 60
Study: 24144505

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (specifics not provided)
Number of subjects: 47
Study: 24144643

Group type: EXPERIMENTAL
Intervention: GEP70 risk score >-0.26
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Combination of elevated serum free light chain, M-spike, and GEP70 risk score
Number of subjects: 331

Group type: COMPARATOR
Intervention: Absence of elevated serum free light chain, M-spike, and GEP70 risk score
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Detection of multiple (>1) focal lesions by MRI
Number of subjects: 331
Study: 24145340

Group type: EXPERIMENTAL
Intervention: Dose-escalated hypofractionated radiotherapy (RT) with total doses ranging from 57 to 85.5 Gy in 25 daily fractions over 5 weeks using intensity-modulated radiotherapy.
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Dose-escalated hypofractionated radiotherapy (RT)
Number of subjects: 79
Study: 24145345

Group type: EXPERIMENTAL
Intervention: Nivolumab with vaccine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nivolumab at 3 mg/kg with or without peptide vaccine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 90
Study: 24145457

Group type: EXPERIMENTAL
Intervention: Strain Relaxation Index (SRI)
Number of subjects: 1544
Study: 24145657

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0
Study: 24145802

Group type: EXPERIMENTAL
Intervention: Dehydrated patients (urinary specific gravity 1.020 or higher)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Euhydrated patients (urinary specific gravity less than 1.020)
Number of subjects: 45
Study: 24145880

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (ATVr) 300/100 mg every 24 hours
Number of subjects: 14

Group type: COMPARATOR
Intervention: Unboosted atazanavir (200 mg every 12 hours)
Number of subjects: 14
Study: 24145879

Group type: EXPERIMENTAL
Intervention: Raltegravir as a film-coated tablet 400 mg twice daily (6 to <19 years, and ≥ 25 kg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Raltegravir as a chewable tablet 6 mg/kg (maximum dose 300 mg) twice daily (2 to <12 years)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Raltegravir (both formulations)
Number of subjects: 96
Study: 24146089

Group type: EXPERIMENTAL
Intervention: CTGF plus NT-proBNP
Number of subjects: 212

Group type: COMPARATOR
Intervention: NT-proBNP alone
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: CTGF levels
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: CTGF levels in HFREF patients
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: CTGF levels in HFPEF patients
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: CTGF levels in AHF patients
Number of subjects: 212
Study: 24146220

Group type: EXPERIMENTAL
Intervention: Panitumumab (9 mg/kg) + Gemcitabine (1000 mg/m(2)) + Irinotecan (100 mg/m(2))
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Panitumumab + Gemcitabine + Irinotecan
Number of subjects: 35
Study: 24146249

Group type: EXPERIMENTAL
Intervention: Antithrombin levels <70%
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Antithrombin levels 70-80%
Number of subjects: 823

Group type: COMPARATOR
Intervention: Antithrombin levels >80%
Number of subjects: 823
Study: 24148552

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily (single dose on day 1 and multiple doses on days 4-10)
Number of subjects: 14
Study: 24148568

Group type: EXPERIMENTAL
Intervention: r-TVT
Number of subjects: 240
Study: 24150470

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24150759

Group type: EXPERIMENTAL
Intervention: Subfoveal placement of active microelectronic subretinal implant
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Parafoveal placement of active microelectronic subretinal implant
Number of subjects: 20
Study: 24151550

Group type: EXPERIMENTAL
Intervention: Plant stanol ester (STAEST) in soymilk-based minidrink (2.7 g/d, 65 mL/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (same drink without added plant stanols)
Number of subjects: 56
Study: 24152822

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring (HBPM)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ambulatory Blood Pressure Monitoring (ABPM)
Number of subjects: 104
Study: 24152880

Group type: EXPERIMENTAL
Intervention: Specialised palliative care (SPC) plus standard treatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 300
Study: 24152982

Group type: EXPERIMENTAL
Intervention: Plasma-free H2S levels in patients with vascular disease (n = 219)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Total nitric oxide (NO) levels in patients with peripheral arterial disease (PAD)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Ratio of plasma free H2S to NO in patients with PAD
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Plasma IL-6, ICAM-1, and TSP-1 levels
Number of subjects: 219
Study: 24153343

Group type: EXPERIMENTAL
Intervention: Soy product intake (highest quartile)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meat intake (highest quartile)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy intake (highest quartile)
Number of subjects: 0
Study: 24153346

Group type: EXPERIMENTAL
Intervention: Full-fat dairy consumption
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Phospholipid fatty acid 17:0
Number of subjects: 86
Study: 24153347

Group type: EXPERIMENTAL
Intervention: Cyclooxygenase inhibitors (NSAIDs) >6 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 150
Study: 24154514

Group type: EXPERIMENTAL
Intervention: Support from healthcare professionals during delivery
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Respect shown towards the baby by healthcare professionals
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Short-term follow-up care received
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Clinically significant long-term post-traumatic stress symptoms (PTSS)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Younger age as a risk factor for PTSS
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Induced abortion prior to stillbirth as a risk factor for PTSS
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Higher parity as a risk factor for PTSS
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Holding the baby as a protective factor against PTSS
Number of subjects: 379
Study: 24155092

Group type: EXPERIMENTAL
Intervention: Direct stenting technique
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Conventional stenting
Number of subjects: 1419
Study: 24155157

Group type: EXPERIMENTAL
Intervention: Tigecycline (100-mg infusion followed by two 50-mg infusions, each administered over 30 minutes)
Number of subjects: 0
Study: 24155635

Group type: EXPERIMENTAL
Intervention: Lapatinib plus letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab-anastrozole
Number of subjects: 0
Study: 24156036

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 102
Study: 24156629

Group type: EXPERIMENTAL
Intervention: Community health coach integration, home blood pressure monitoring, standardized care delivery processes, and improved medication adherence
Number of subjects: 0
Study: 24156961

Group type: EXPERIMENTAL
Intervention: Absorb scaffold
Number of subjects: 30
Study: 24157897

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Paracetamol-Morphine Combination
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paracetamol and Morphine Combination
Number of subjects: 90
Study: 24158379

Group type: EXPERIMENTAL
Intervention: Active indoor group water-pipe smoking (WPS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Passive indoor group water-pipe smoking (WPS)
Number of subjects: 62
Study: 24158411

Group type: EXPERIMENTAL
Intervention: Trastuzumab, lapatinib, and bevacizumab (trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance dose, intravenously every 3 weeks; lapatinib 1250 mg daily; bevacizumab 15 mg/kg intravenously every 3 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Trastuzumab, lapatinib, and bevacizumab
Number of subjects: 26
Study: 24159060

Group type: EXPERIMENTAL
Intervention: tPA plus CLOTBUST-HF device (2-hour therapeutic exposure to 2-MHz pulsed-wave ultrasound)
Number of subjects: 20

Group type: COMPARATOR
Intervention: tPA alone (standard-dose intravenous)
Number of subjects: 20
Study: 24159258

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg once daily
Number of subjects: 0
Study: 24159343

Group type: EXPERIMENTAL
Intervention: Tongue Diagnosis System (TDS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 60
Study: 24161160

Group type: EXPERIMENTAL
Intervention: Rilpivirine (25 mg once daily) co-administered with ethinylestradiol (35 μg)/norethindrone (1 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rilpivirine (25 mg once daily)
Number of subjects: 18
Study: 24161161

Group type: EXPERIMENTAL
Intervention: Single intravenous dose of tocilizumab (TCZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral contraceptives (OC; norethindrone (NE) and ethinyl estradiol (EE))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral contraceptives (OC) with or without a single dose of TCZ
Number of subjects: 0